vs

Side-by-side financial comparison of OptimizeRx Corp (OPRX) and PRO DEX INC (PDEX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $18.7M, roughly 1.7× PRO DEX INC). OptimizeRx Corp runs the higher net margin — 15.6% vs 11.7%, a 3.9% gap on every dollar of revenue. On growth, PRO DEX INC posted the faster year-over-year revenue change (11.1% vs -0.2%). OptimizeRx Corp produced more free cash flow last quarter ($7.1M vs $3.5M). Over the past eight quarters, OptimizeRx Corp's revenue compounded faster (28.0% CAGR vs 14.3%).

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

Pro Dex Inc is a precision manufacturing enterprise that produces custom machined components, subassemblies and finished products primarily for medical device original equipment manufacturers, as well as clients in the aerospace and industrial sectors, with its core operating market covering North America.

OPRX vs PDEX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.7× larger
OPRX
$32.2M
$18.7M
PDEX
Growing faster (revenue YoY)
PDEX
PDEX
+11.4% gap
PDEX
11.1%
-0.2%
OPRX
Higher net margin
OPRX
OPRX
3.9% more per $
OPRX
15.6%
11.7%
PDEX
More free cash flow
OPRX
OPRX
$3.6M more FCF
OPRX
$7.1M
$3.5M
PDEX
Faster 2-yr revenue CAGR
OPRX
OPRX
Annualised
OPRX
28.0%
14.3%
PDEX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
OPRX
OPRX
PDEX
PDEX
Revenue
$32.2M
$18.7M
Net Profit
$5.0M
$2.2M
Gross Margin
74.8%
30.8%
Operating Margin
26.6%
17.5%
Net Margin
15.6%
11.7%
Revenue YoY
-0.2%
11.1%
Net Profit YoY
6535.9%
7.2%
EPS (diluted)
$0.27
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPRX
OPRX
PDEX
PDEX
Q4 25
$32.2M
$18.7M
Q3 25
$26.1M
$18.5M
Q2 25
$29.2M
$17.5M
Q1 25
$21.9M
$17.4M
Q4 24
$32.3M
$16.8M
Q3 24
$21.3M
$14.9M
Q2 24
$18.8M
$15.0M
Q1 24
$19.7M
$14.3M
Net Profit
OPRX
OPRX
PDEX
PDEX
Q4 25
$5.0M
$2.2M
Q3 25
$779.0K
$4.7M
Q2 25
$1.5M
$1.2M
Q1 25
$-2.2M
$3.3M
Q4 24
$-78.0K
$2.0M
Q3 24
$-9.1M
$2.5M
Q2 24
$-4.0M
$1.6M
Q1 24
$-6.9M
$655.0K
Gross Margin
OPRX
OPRX
PDEX
PDEX
Q4 25
74.8%
30.8%
Q3 25
67.2%
29.0%
Q2 25
63.8%
19.9%
Q1 25
60.9%
33.3%
Q4 24
68.1%
30.2%
Q3 24
63.1%
34.6%
Q2 24
62.2%
27.2%
Q1 24
62.0%
28.0%
Operating Margin
OPRX
OPRX
PDEX
PDEX
Q4 25
26.6%
17.5%
Q3 25
7.9%
16.8%
Q2 25
10.9%
7.7%
Q1 25
-9.6%
20.9%
Q4 24
11.2%
16.0%
Q3 24
-40.2%
20.2%
Q2 24
-19.9%
15.6%
Q1 24
-25.5%
15.5%
Net Margin
OPRX
OPRX
PDEX
PDEX
Q4 25
15.6%
11.7%
Q3 25
3.0%
25.3%
Q2 25
5.2%
6.8%
Q1 25
-10.0%
18.8%
Q4 24
-0.2%
12.1%
Q3 24
-42.8%
16.6%
Q2 24
-21.3%
10.6%
Q1 24
-35.0%
4.6%
EPS (diluted)
OPRX
OPRX
PDEX
PDEX
Q4 25
$0.27
$0.66
Q3 25
$0.04
$1.40
Q2 25
$0.08
$0.33
Q1 25
$-0.12
$0.98
Q4 24
$0.00
$0.61
Q3 24
$-0.50
$0.75
Q2 24
$-0.22
$0.44
Q1 24
$-0.38
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPRX
OPRX
PDEX
PDEX
Cash + ST InvestmentsLiquidity on hand
$23.4M
$6.1M
Total DebtLower is stronger
$26.3M
Stockholders' EquityBook value
$128.3M
$41.6M
Total Assets
$176.9M
$62.3M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPRX
OPRX
PDEX
PDEX
Q4 25
$23.4M
$6.1M
Q3 25
$19.5M
$10.1M
Q2 25
$16.6M
$6.8M
Q1 25
$16.6M
$5.5M
Q4 24
$13.4M
$4.7M
Q3 24
$16.1M
$7.8M
Q2 24
$6.8M
Q1 24
$7.8M
Total Debt
OPRX
OPRX
PDEX
PDEX
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
$15.4M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
$12.0M
Q1 24
$37.8M
Stockholders' Equity
OPRX
OPRX
PDEX
PDEX
Q4 25
$128.3M
$41.6M
Q3 25
$122.3M
$41.5M
Q2 25
$119.3M
$36.6M
Q1 25
$116.3M
$35.3M
Q4 24
$117.0M
$31.8M
Q3 24
$114.5M
$30.9M
Q2 24
$121.0M
$30.9M
Q1 24
$122.5M
$30.9M
Total Assets
OPRX
OPRX
PDEX
PDEX
Q4 25
$176.9M
$62.3M
Q3 25
$170.3M
$64.3M
Q2 25
$169.3M
$61.2M
Q1 25
$167.8M
$64.3M
Q4 24
$171.2M
$60.4M
Q3 24
$165.2M
$54.3M
Q2 24
$172.9M
$52.5M
Q1 24
$176.4M
$50.5M
Debt / Equity
OPRX
OPRX
PDEX
PDEX
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
0.42×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
0.39×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPRX
OPRX
PDEX
PDEX
Operating Cash FlowLast quarter
$7.1M
$3.6M
Free Cash FlowOCF − Capex
$7.1M
$3.5M
FCF MarginFCF / Revenue
22.0%
18.8%
Capex IntensityCapex / Revenue
0.0%
0.4%
Cash ConversionOCF / Net Profit
1.41×
1.63×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPRX
OPRX
PDEX
PDEX
Q4 25
$7.1M
$3.6M
Q3 25
$3.2M
$2.3M
Q2 25
$4.6M
$-173.0K
Q1 25
$3.9M
$754.0K
Q4 24
$198.0K
$-4.2M
Q3 24
$1.8M
$1.9M
Q2 24
$782.0K
$1.0M
Q1 24
$2.1M
$4.1M
Free Cash Flow
OPRX
OPRX
PDEX
PDEX
Q4 25
$7.1M
$3.5M
Q3 25
$3.2M
$2.2M
Q2 25
$4.6M
Q1 25
$3.8M
$574.0K
Q4 24
$181.0K
$-4.7M
Q3 24
$1.8M
$1.5M
Q2 24
$737.0K
Q1 24
$2.1M
$4.0M
FCF Margin
OPRX
OPRX
PDEX
PDEX
Q4 25
22.0%
18.8%
Q3 25
12.2%
11.9%
Q2 25
15.6%
Q1 25
17.5%
3.3%
Q4 24
0.6%
-27.9%
Q3 24
8.3%
9.8%
Q2 24
3.9%
Q1 24
10.6%
27.7%
Capex Intensity
OPRX
OPRX
PDEX
PDEX
Q4 25
0.0%
0.4%
Q3 25
0.0%
0.5%
Q2 25
0.0%
Q1 25
0.1%
1.0%
Q4 24
0.1%
3.2%
Q3 24
0.1%
2.9%
Q2 24
0.2%
Q1 24
0.2%
0.8%
Cash Conversion
OPRX
OPRX
PDEX
PDEX
Q4 25
1.41×
1.63×
Q3 25
4.11×
0.49×
Q2 25
2.98×
-0.14×
Q1 25
0.23×
Q4 24
-2.03×
Q3 24
0.77×
Q2 24
0.66×
Q1 24
6.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons